期刊
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021
卷 72, 期 -, 页码 447-458出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-080819-044918
关键词
cholesterol; coronary artery disease; genetics; inflammation; lipoproteins; triglycerides
Currently, statins, ezetimibe, and PCSK9 inhibitors are the standard of care for the prevention and treatment of coronary artery disease, but it remains the leading cause of death worldwide. Many new therapies targeting various lipid traits or inflammation have recently received approval or fared favorably in clinical trials, promising to transform the care of patients at risk for life-threatening coronary events.
Statins, ezetimibe, and PCSK9 inhibitors are currently the standard of care for the prevention and treatment of coronary artery disease. Despite their widespread use, coronary artery disease remains the leading cause of death worldwide, a fact that pleads for the development of new protective therapies. In no small part due to advances in the field of human genetics, many new therapies targeting various lipid traits or inflammation have recently received approval from regulatory agencies such as the US Food and Drug Administration or fared favorably in clinical trials. This wave of new therapies promises to transform the care of patients at risk for life-threatening coronary events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据